Compare DigitalOcean Holdings Inc (DOCN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? DigitalOcean Holdings Inc trades at $125.66 (market cap $14.57B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.2× DigitalOcean Holdings Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DOCN | REGN | |
|---|---|---|
Market Cap | $14.57B | $76.14B |
Volume | 2,261,786 | 500,239 |
Sector | Technology | Health |
52-Week High | $181.29 | $852.03 |
52-Week Low | $37.30 | $557.73 |
Typical Hold Time | 43 Days | 107 Days |
Enterprise Value | $15.33B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $127.28, down 2.89% today, with strong technical support at $126 and resistance at $130. The company shows robust revenue growth from $576M in 2022 to $901M in 2025, with net income turning positive to $259M. Recent AI-focused product launches including Agent Droplets and Managed Agents position the company for continued growth in cloud services.
Despite high valuation multiples (P/E 57.85, P/S 14.34), analyst consensus remains bullish with a $172.73 price target representing 36% upside. Key risks include capital intensity from expansion and high debt levels, while institutional accumulation and consistent earnings beats support the growth narrative.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
